CDKN2B and cancer: Altogether, our findings not only reveal important insights that link arginine methylation and lysine methylation to directly modulate CDKN2B transcription, but also pave the way to revolutionize our therapeutic options by blocking either PRMT5/EZH2 activities or the associated transcription regulatory network to treat CRC and even probably other cancers.